'Stop adc development services' presentation slideshows

Seattle Genetics Launched the Phase II Clinical Trial of Antibody-drug Conjugate (ADC) Called Enfortumab Vedotin

Enfortumab vedotin is an experimental ADC drug linked by a monoclonal antibody targeting the nectin-4 protein and a microtubule disruptor vedotin (MMAE) via Seattle Genetics' proprietary conjugated technology.

104 views • 2 slides

FDA Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer

"Sacituzumab govitecan, the most advanced candidate in Immunomedics, is a novel first-in-class ADC drug consisting of anti-TROP-2 monoclonal antibody and cytotoxic SN-38. In contrast, Immunomedics uses the moderately toxic drug SN-38 instead of the super cytotoxic drug calicheamicin. "

135 views • 2 slides

Seattle Genetics Launched the Phase II Clinical Trial of Antibody-drug Conjugate (ADC) Called Enfortumab Vedotin

26 views • 2 slides

FDA Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer

Sacituzumab govitecan, the most advanced candidate in Immunomedics, is a novel first-in-class ADC drug consisting of anti-TROP-2 monoclonal antibody and cytotoxic SN-38. In contrast, Immunomedics uses the moderately toxic drug SN-38 instead of the super cytotoxic drug calicheamicin. Learn more from https://www.creative-biolabs.com/blog/adc/fda-grants-priority-review-for-sacituzumab-govitecan-triple-negative-breast-cancer/

29 views • 2 slides